Dr. Andrew Retter, Chief Medical Officer at Volition, said: "This is a significant milestone for our Nu.Q® Discover program: the first human clinical study with a pharmaceutical company sponsor ...

Dr Andrew Retter, Chief Medical Officer at Volition said: "We are excited to report the findings of this large-scale independent clinical study, the culmination of many years work. Nu.Q® NETs ...

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has signed an agreement with a leading pharmaceutical company to utilize Volition's ...